Pyrrolidinone racetam (parent racemate of levetiracetam)

Plain-language summaryIntrigue 32 / 100

Etiracetam is the racemic precursor of levetiracetam. The R-enantiomer is largely inactive; the S-enantiomer is levetiracetam. Used as a research tool to study the levetiracetam mechanism. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

16/100

The racemic parent of levetiracetam, superseded by chiral resolution and offering no research advantage over the pure active enantiomer

Look, etiracetam is essentially a solved problem in medicinal chemistry that nobody needed to return to. UCB Pharma developed it in the 1970s as a piracetam analog, investigated it briefly in early antiseizure pharmacology, then did what any competent chemist would do: resolved the racemate, identified that the S-enantiomer carries essentially all of the SV2A-mediated activity, and shelved the parent compound. That’s the whole story. The field moved on in the 1980s and hasn’t looked back.

The mechanism picture reflects this directly. SV2A-mediated pharmacology is well-characterized at this point, and levetiracetam’s binding profile has been studied extensively across multiple labs and decades. Etiracetam doesn’t add any mechanistic insight you don’t already get from levetiracetam. It just dilutes the active compound 1:1 with a biologically inert R-enantiomer at the primary target. If you want to probe SV2A, you use levetiracetam. If you want the R-enantiomer specifically, you source it separately. There’s no design where the racemate is the right tool.

On differentiation, this is about as close to “strictly worse than alternatives” as you’ll find in any research library. Levetiracetam is on formulary globally, has decades of well-characterized pharmacology, and answers the SV2A question better by construction. The differentiation score bottoms out because the compound’s own development history is the argument against it.

The evidence picture is correspondingly thin. Contemporary literature treats etiracetam almost entirely as a footnote in the levetiracetam origin story. There are no active clinical programs, no replicated modern preclinical investigations, no contemporary pharmacokinetic or pharmacodynamic studies in humans conducted on etiracetam as an object of interest in its own right. Citations to etiracetam in modern papers nearly always take the form: “levetiracetam was developed from its racemate” and nothing more.

We do score bench value modestly above zero because theres a narrow legitimate use case: comparative studies examining whether the R-enantiomer contributes anything to observed in vivo effects through off-target mechanisms, or analytical chemistry reference work. That’s real. But it’s a niche probe application for a very specific research question, not an active research target for a serious program. Honestly, the only reason this compound belongs in a library at all is completeness, not because any researcher should be prioritizing it in 2025.

Novelty: 12
Mechanism promise: 20
In-category differentiation: 8
Evidence quality: 18
Translational signal: 12
Research bench value: 30

Rationale Etiracetam scores low across nearly every axis because it is literally superseded by its own chiral resolution; levetiracetam is strictly better for any SV2A research, and the R-enantiomer is biologically inert at the primary target. The only residual bench value is as a chirality reference or comparative probe in narrow enantioselectivity studies, and even that use case is thin.

Pyrrolidinone racetam (parent racemate of levetiracetam)

The racemic parent compound of levetiracetam, retained primarily as a research chemical and historical reference compound.

Abstract

Etiracetam (UCB 6215; α-ethyl-2-oxo-1-pyrrolidineacetamide; CAS 33996-58-6; molecular formula C8H14N2O2; molecular weight 170.21) is the racemic parent compound of levetiracetam, originally developed at UCB Pharma in the 1970s as a piracetam analog with a 2-ethyl substitution on the acetamide. The compound is a 1:1 mixture of (R)- and (S)-enantiomers; the (S)-enantiomer (levetiracetam) carries essentially all of the SV2A-mediated antiseizure activity, while the (R)-enantiomer is biologically inactive at the same target. Etiracetam was investigated in early antiseizure pharmacology in the 1980s but was superseded by the chiral resolution to levetiracetam, which became the marketed product. The compound has no current regulatory approval and is sold as a research chemical. Pharmacokinetics and dose ranges parallel levetiracetam at 2-fold the dose to account for the inactive enantiomer. There is essentially no contemporary clinical literature on etiracetam itself; references largely cite it as the parent of levetiracetam.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-035Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: Pyrrolidinone racetam (parent racemate of levetiracetam)

Etiracetam

Abstract

Read the full monograph